Editas Medicine (EDIT) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Editas Medicine Reshapes Future With In Vivo Focus Amid Major Workforce Cuts
Yahoo Finance13:26 ET
Editas Medicine Is Maintained at Sector Perform by RBC Capital
Dow Jones12:38 ET · Ratings
RBC Capital Maintains Sector Perform on Editas Medicine, Lowers Price Target to $4
Benzinga12:28 ET · Ratings
Editas Medicine Maintains Hold Rating Amid Strategic Shifts and Financial Challenges
TipRanks11:05 ET · Ratings
Walmart To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Friday
BenzingaDec 13 10:22 ET
This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
BenzingaDec 13 10:05 ET

Comments

Broke Trader

Yesterday 05:08

Editas Medicine Inc - Expected Costs of $55 Million to $70 Million

$Editas Medicine (EDIT.US)$

Jaguar8

Yesterday 05:01

NEWS

$Editas Medicine (EDIT.US)$
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
Thursday, 12th December at 4:00 pm
• Focus on in vivo CRISPR-edited medicines based on Editas researchers' recent scientific progress in multiple tissues:
◦ Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing and HbF induction in a humanized mouse model for treatment of sickle cell...

Stock_Drift

Dec 9 14:23

$Editas Medicine (EDIT.US)$

1

Trytosaveabit

Oct 22 06:22

$Editas Medicine (EDIT.US)$ Editas Medicine Announced In Vivo Preclinical Proof Of Concept Data Of Hematopoietic Stem And Progenitor Cell Editing And Fetal Hemoglobin Induction In Humanized Mice Engrafted With Human Hematopoietic Stem Cells And Lacking Their Own Hematopoietic Cells
Benzinga· 2 mins ago
The Company observed high levels of editing of the HBG1/2 promoter, leveraging clinically validated upregulation strategy, utilizing a novel and Editas-proprietary targeted lipid nanoparticle (tLNP...

Jaguar8

Oct 3 23:44

AH NEWS TODAY

$Editas Medicine (EDIT.US)$
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Editas Medicine (Nasdaq: EDIT) has announced a $57 million upfront cash payment from DRI Healthcare Trust in exchange for certain future license fees and payments under its Cas9 license agreement with Vertex Pharmaceuticals. This non-dilutive capital will support Editas Medicine's pipeline development and strategic priorities.
The deal includes up to 100% of future ann...

3

1

EDIT Editas Medicine

Trade Overview

Capital Trend

News

Comments